Gestational Trophoblastic Disease Market: The increasing prevalence of risk factors such as a rise in ectopic pregnancies and history of miscarriages are projected to boost the market growth at a healthy CAGR

Pune, India, October 2022/MRFR Press Release/- Market Research Future has published a half-cooked research report on the global gestational trophoblastic disease market.

Market Highlights

The Gestational Trophoblastic Disease Market is expected to reach USD 2.3 Billion by 2030 at 4.20% CAGR during the forecast period 2022-2030

Gestational trophoblastic disease (GTD) is a cluster of rare tumors that include abnormal growth of cells inside a woman's uterus. It arises from placental trophoblastic tissue and is characterized by β-subunit of human chorionic gonadotrophin (β HCG). The increasing prevalence of risk factors such as smoking, sexually transmitted diseases (STD), history of miscarriages, and high maternal age are expected to fuel the growth of the market during the forecast period. Rise in ectopic pregnancies is also a significant factor which causes GTD. According to the National Center for Biotechnology Information (NCBI), the risk of ectopic pregnancy is 20 times higher in women who smoke. On the other hand, high risks of recurrence and complications that may occur after the therapy and treatment procedure may hinder the growth of the market during the forecast period.

The global gestational trophoblastic disease market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic partnerships to strengthen its market position. For instance, in September 2018, Novartis AG entered into a license and collaboration agreement with Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company which develops therapies for cancer and degenerative diseases in Greater China.

Regional Analysis

The market in the Americas is expected to dominate the global Gestational Trophoblastic Disease market during the forecast period owing to the increased awareness about the disease and the favorable reimbursement scenario in this region. Additionally, the rise in a number of marketing approvals, as well as product approvals in the field of oncology. The European market is expected to be the second-largest due to the substantial support of the government in research and development in this field. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to growing disposable income, increasing patient population, and discrepancies between hospital- and population-based data. The market in the Middle East and Africa is likely to account for the smallest share of the global gestational trophoblastic disease market. The growth of the market in this region can be attributed to the growing expenditure for the healthcare sector and developing healthcare infrastructure.

Explore In-depth Details: Gestational Trophoblastic Disease Market Research Report

Segmentation

The global gestational trophoblastic disease market has been segmented into type, treatment, and end-user.

The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.

The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole.

The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy. Surgical procedures are the most preferred treatment option by the doctors, which is why it is anticipated to be the largest growing segment in the market, whereas chemotherapy segment is the fastest-growing, as there are new innovations coming up in the chemotherapy field such as single-agent and multiagent chemotherapies.

The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.

The market, by end-user, has been segmented into hospital and clinics, diagnostic centers, and others.

Key Players

Some of the key players in the global gestational trophoblastic disease market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, Antares Pharma, Mylan N.V., Novartis AG, BP Pharmaceuticals Laboratories Company, Fresenius Kabi AG, Accord Healthcare, Inc., Eli Lilly and Company, Sanofi, Bayer AG, Amgen Inc. and Merck.